Literature DB >> 6145470

Relaxation of cat tracheobronchial and pulmonary arterial smooth muscle by vasoactive intestinal peptide: lack of influence by peptidase inhibitors.

R J Altiere, L Diamond.   

Abstract

Vasoactive intestinal peptide (VIP) caused concentration-dependent relaxation in precontracted segments of trachea, hilar bronchus, intrapulmonary bronchus and intrapulmonary artery (IPA) isolated from cat lungs. VIP-induced relaxation responses were abolished by preincubation of tissues with the proteolytic enzyme, alpha-chymotrypsin (2 units ml-1). At the concentration employed, alpha-chymotrypsin treatment did not adversely affect tissue viability as isoprenaline and bethanechol continued to relax airways and IPA, respectively. Aprotinin prevented enzymatic degradation of VIP by alpha-chymotrypsin as demonstrated by the ability of VIP to relax tissues incubated with both the peptidase inhibitor and alpha-chymotrypsin. A spectrum of peptidase inhibitors, including aprotinin, leupeptin, bestatin, bacitracin, beta-phenylpropionic acid and captopril, individually or in combination, did not augment the relaxant effects of VIP in isolated pulmonary tissues. These results suggest that local enzymatic degradation may not be a primary route for inactivation of VIP in cat isolated airways and IPA. If VIP acts as a neurotransmitter in these tissues, a mechanism other than enzymatic proteolysis may be responsible for terminating its action.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145470      PMCID: PMC1987047          DOI: 10.1111/j.1476-5381.1984.tb10766.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

Review 1.  A rationale for the application of trasylol as a protease inhibitor in radioimmunoassay.

Authors:  E S Zyznar
Journal:  Life Sci       Date:  1981-04-27       Impact factor: 5.037

2.  Vasoactive intestinal peptide: a possible transmitter of nonadrenergic relaxation of guinea pig airways.

Authors:  Y Matsuzaki; Y Hamasaki; S I Said
Journal:  Science       Date:  1980-12-12       Impact factor: 47.728

3.  Degradation of vasoactive intestinal polypeptide by tissue homogenates.

Authors:  T N Keltz; E Straus; R S Yalow
Journal:  Biochem Biophys Res Commun       Date:  1980-01-29       Impact factor: 3.575

4.  Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects.

Authors:  R D Dey; W A Shannon; S I Said
Journal:  Cell Tissue Res       Date:  1981       Impact factor: 5.249

5.  A nonadrenergic vagal inhibitory pathway to feline airways.

Authors:  L Diamond; M O'Donnell
Journal:  Science       Date:  1980-04-11       Impact factor: 47.728

6.  Vasoactive intestinal polypoptide: inactivation in liver and potentiation in lung of anesthetized dogs (384699).

Authors:  S Kitamura; T Yoshida; S I Said
Journal:  Proc Soc Exp Biol Med       Date:  1975-01

7.  Radioimmunoassay of vasoactive intestinal polypeptide (VIP) in plasma.

Authors:  J Fahrenkrug; O V Schaffalitzky de Muckadell
Journal:  J Lab Clin Med       Date:  1977-06

8.  Vasoactive intestinal peptide as a neurotransmitter in the cerebral circulation.

Authors:  S P Duckles; S I Said
Journal:  Eur J Pharmacol       Date:  1982-03-12       Impact factor: 4.432

9.  Leupeptin, a protease inhibitor, decreases protein degradation in normal and diseased muscles.

Authors:  P Libby; A L Goldberg
Journal:  Science       Date:  1978-02-03       Impact factor: 47.728

10.  Evidence against vasoactive intestinal polypeptide being the non-adrenergic, non-cholinergic inhibitory transmitter released from nerves supplying the smooth muscle of the guinea-pig taenia coli.

Authors:  I Mackenzie; G Burnstock
Journal:  Eur J Pharmacol       Date:  1980-10-17       Impact factor: 4.432

View more
  10 in total

1.  Effects of epithelium removal on relaxation of airway smooth muscle induced by vasoactive intestinal peptide and electrical field stimulation.

Authors:  S G Farmer; J Togo
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

2.  Proceedings of the British Pharmacological Society. Ireland, 6th-8th July, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

3.  Modulation of cholinergic neurotransmission by the peptide VIP, VIP antiserum and VIP antagonists in dog and cat trachea.

Authors:  H Hakoda; Y Ito
Journal:  J Physiol       Date:  1990-09       Impact factor: 5.182

4.  Pulmonary clearance of vasoactive intestinal peptide.

Authors:  M P Barrowcliffe; A Morice; J G Jones; P S Sever
Journal:  Thorax       Date:  1986-02       Impact factor: 9.139

5.  The effects of vasoactive intestinal peptide (VIP) antagonists, and VIP and peptide histidine isoleucine antisera on non-adrenergic, non-cholinergic relaxations of tracheal smooth muscle.

Authors:  J L Ellis; S G Farmer
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

6.  The effect of vasoactive intestinal peptide on smooth muscle tone and mucus secretion from the ferret trachea.

Authors:  S E Webber; J G Widdicombe
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

7.  The release of a non-prostanoid inhibitory factor from rabbit bronchus detected by co-axial bioassay.

Authors:  D Spina; C P Page
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

8.  Regulation of NANC neural bronchoconstriction in vivo in the guinea-pig: involvement of nitric oxide, vasoactive intestinal peptide and soluble guanylyl cyclase.

Authors:  Y H Lei; P J Barnes; D F Rogers
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

9.  Role of nitric oxide in non-adrenergic, non-cholinergic relaxation and modulation of excitatory neuroeffector transmission in the cat airway.

Authors:  L Jing; R Inoue; K Tashiro; S Takahashi; Y Ito
Journal:  J Physiol       Date:  1995-02-15       Impact factor: 5.182

10.  Effects of peptidases on non-adrenergic, non-cholinergic inhibitory responses of tracheal smooth muscle: a comparison with effects on VIP- and PHI-induced relaxation.

Authors:  J L Ellis; S G Farmer
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.